GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Operating Income

Q BioMed (Q BioMed) Operating Income : $-2.73 Mil (TTM As of Feb. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Operating Income?

Q BioMed's Operating Income for the three months ended in Feb. 2023 was $-0.45 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2023 was $-2.73 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Q BioMed's Operating Income for the three months ended in Feb. 2023 was $-0.45 Mil. Q BioMed's Revenue for the three months ended in Feb. 2023 was $0.00 Mil. Therefore, Q BioMed's Operating Margin % for the quarter that ended in Feb. 2023 was %.

Q BioMed's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Q BioMed's annualized ROC % for the quarter that ended in Feb. 2023 was -23.34%. Q BioMed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2023 was %.


Q BioMed Operating Income Historical Data

The historical data trend for Q BioMed's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Operating Income Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.02 -8.02 -13.15 -7.39 -3.45

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.16 -0.93 -0.78 -0.57 -0.45

Q BioMed Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Q BioMed  (OTCPK:QBIO) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Q BioMed's annualized ROC % for the quarter that ended in Feb. 2023 is calculated as:

ROC % (Q: Feb. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2022 ) + Invested Capital (Q: Feb. 2023 ))/ count )
=-1.78 * ( 1 - 0% )/( (7.645 + 7.606)/ 2 )
=-1.78/7.6255
=-23.34 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Q BioMed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2022  Q: Feb. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.78/( ( (0 + max(-4.001, 0)) + (0 + max(-5.812, 0)) )/ 2 )
=-1.78/( ( 0 + 0 )/ 2 )
=-1.78/0
= %

where Working Capital is:

Working Capital(Q: Nov. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.012 + 0 + 0.01) - (3.932 + 0 + 0.090999999999999)
=-4.001

Working Capital(Q: Feb. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.011) - (5.731 + 0 + 0.092000000000001)
=-5.812

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Q BioMed's Operating Margin % for the quarter that ended in Feb. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Feb. 2023 )/Revenue (Q: Feb. 2023 )
=-0.445/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Q BioMed Operating Income Related Terms

Thank you for viewing the detailed overview of Q BioMed's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Q BioMed (Q BioMed) Business Description

Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1